Android app on Google Play

VIVUS (VVUS) Reports Publication of Signifianct Data from Recent Qsymia Study

February 1, 2013 7:15 AM EST Send to a Friend
VIVUS, Inc. (Nasdaq: VVUS) announces the publication of a study concluding that weight loss resulting from treatment with Qsymia (phentermine and topiramate extended-release) capsules CIV led to significant improvements in cholesterol, blood pressure and triglycerides in obese and overweight patients experiencing one or more of these associated conditions. The improvements were significantly greater among patients who lost 10% or more of their starting weight.

"This provides clear evidence that patients with hypertension or high cholesterol treated with Qsymia for one year experienced significant weight loss and clinically meaningful improvements in their underlying cardiovascular risk factors," said Suzanne Oparil, M.D., Director of the Vascular Biology and Hypertension Program, University of Alabama at Birmingham, and an investigator in the study. "The ability to improve underlying risk factors is another reason physicians should proactively discuss the medical treatment of obesity with their patients who have failed lifestyle modification alone."




You May Also Be Interested In


Related Categories

Corporate News, FDA, Management Comments

Add Your Comment